In 2015, the U.S. Food and Drug Administration (FDA) invited comment on its draft guidance for the regulatory oversight of laboratory-developed tests (LDTs). With a focus on genetic and genomic testing, ASHG submitted comments on the proposed regulatory oversight of such tests.
Related:
- Comments Submitted in Response to FDA’s Draft Guidance: Framework for Regulatory Oversight of Laboratory Developed Tests (February 2015)